In a 12-month study of 339 Second Nature members published in JMIR Formative Research, members taking tirzepatide (Mounjaro) lost an average of 22.1% of their body weight, and those taking semaglutide (Wegovy) lost 17.1%, in line with the averages seen in the original clinical trials
A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimers dementia
Preclinical studies supply the bulk of mechanistic information, with sparse early clinical reports for a few compounds
This excess risk stems from multiple factors including accelerated atherosclerosis, increased inflammatory state, abnormal blood clotting tendencies, and the metabolic damage caused by chronic hyperglycemia
Contraindications & Precautions
Available from: FDA approval for GLP-1 Agonist in patients with MASH